Riley Hospital for Children at Indiana University Health

1. Vertex Pharmaceuticals Incorporated $1,115,685 46 payments
2. Novo Nordisk AS $122,518 550 payments
3. E.R. Squibb & Sons, L.L.C. $73,412 2 payments
4. Fresenius Kabi USA, LLC $49,359 38 payments
5. AbbVie, Inc. $19,904 5 payments
6. Pacira Pharmaceuticals Incorporated $5,430 4 payments
7. Boehringer Ingelheim Italia S.p.A. $583 22 payments
8. Boehringer Ingelheim France S.A.S. $323 12 payments

1. A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis $159,785 3 payments
2. A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation $139,531 4 payments
3. A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age $126,086 3 payments
4. Nn8640-4467 $122,518 550 payments
5. Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years $110,008 2 payments
6. A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF) $107,134 4 payments
7. A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older $96,604 3 payments
8. Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation $73,496 5 payments
9. Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del $59,418 4 payments
10. A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older $59,375 2 payments

1. Overhead $49,359 38 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.